Background Approximately 75% of objective responses to anti–programmed death 1 (PD-1)
therapy in patients with melanoma are durable, lasting for years, but delayed relapses have …

Summary PD-L1 and PD-L2 are ligands for the PD-1 immune inhibiting checkpoint that can
be induced in tumors by interferon exposure, leading to immune evasion. This process is …

Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed
death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary …

The immune checkpoint therapy is a relatively recent strategy that aims to tweak the immune
system to effectively attack cancer cells. The understanding of the immune responses and …

To understand the genetic drivers of immune recognition and evasion in colorectal cancer,
we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as …

The rapidly advancing field of cancer immunotherapy is currently limited by the scarcity of
noninvasive and quantitative technologies capable of monitoring the presence and …

Synthetic receptor signalling has the potential to endow adoptively transferred T cells with
new functions that overcome major barriers in the treatment of solid tumours, including the …

Expression of viral proteins frequently includes non-canonical decoding events ('recoding')
during translation.'2A'oligopeptides drive one such event, termed 'stop-carry on'recoding …

Abstract Purpose: PLX4032 (RG7204), an oncogenic BRAF kinase inhibitor undergoing
clinical evaluation, has high response rates in early clinical trials in patients with advanced …

BRAF inhibitors are highly effective therapies for the treatment of BRAF V600-mutated
melanoma, with the main toxicity being a variety of hyperproliferative skin conditions due to …